CHAPTER IX HEALTH TECH ENTREPRENEURSHIP: BUSINESS MODELS AND DIGITAL BUSINESS STRATEGY
Learning
Outcomes
Upon
completing this module, students are expected to be able to:
þ
Analyze
the current landscape of the global and Indonesian digital health market,
including growth drivers, key players, and emerging investment trends
þ
Evaluate
and differentiate the major business model archetypes applied in health
technology ventures, including their advantages, limitations, and contextual
applicability
þ
Develop
a coherent value proposition for a health technology product or service that
demonstrates a clear problem-solution fit and a defensible competitive position
þ
Identify
and characterize distinct customer segments within the health technology
ecosystem and design appropriate engagement strategies for each
þ
Construct
a structured go-to-market strategy for a health technology startup,
encompassing product development approach, launch tactics, and distribution
channel selection
þ
Assess
the principal scaling challenges encountered by health technology companies and
propose evidence-based strategies to address regulatory, operational, and
organizational growth barriers
þ
Design
a viable and contextually appropriate business plan for a health technology
venture within the Indonesian healthcare ecosystem
A.
HEALTH TECH MARKET LANDSCAPE
Market
Size and Growth Projections
The Indonesian
digital health market has entered a phase of sustained and accelerating
expansion, underpinned by converging demographic, technological, and policy
forces. The national digital health market reached an estimated value of USD
2.1 billion in 2023 and is projected to grow substantially through 2030, driven
by increasing smartphone penetration, improved internet connectivity, rising
consumer expectations for accessible healthcare services, and growing
government investment in health digitalization (KenResearch, 2025). Revenue in
the broader Digital Health market in Indonesia is projected to reach USD 2.64
billion in 2025, reflecting the rapid scaling of telemedicine, digital
pharmacy, and remote monitoring services that have become embedded in the
national healthcare delivery fabric (Statista, 2024).
This trajectory
of growth places Indonesia among the most dynamic digital health markets in
Southeast Asia, presenting exceptional opportunities for both entrepreneurial
ventures and established healthcare organizations seeking digital
transformation. The online doctor consultation segment alone is expected to
generate USD 142.39 million by 2025, underscoring the degree to which consumers
across the archipelago have integrated virtual care into their routine
health-seeking behavior (MarketResearchIndonesia, 2025). For hospital managers
and health administrators, understanding this market landscape is not merely an
academic exercise but a strategic imperative, as the boundaries between
traditional healthcare provision and digital health services continue to
dissolve at an accelerating pace.
Several
structural drivers sustain this growth trajectory and merit careful attention
by health management professionals. The COVID-19 pandemic served as a powerful
accelerant for digital health adoption, compressing what might have taken a
decade of gradual behavioral change into a period of months, and this adoption
has proven durable in the post-pandemic environment (AsianInsiders, 2025).
Telemedicine CAGR projections for the remainder of the decade exceed 28 percent
for Indonesia, reflecting not only pandemic-induced habit formation but also
genuine unmet demand in a geographically complex nation where approximately
17,000 islands present a formidable barrier to equitable physical healthcare
access.
Types of Health
Technology
Health
technology constitutes a broad and heterogeneous category encompassing distinct
subsectors that carry different commercial profiles, regulatory requirements,
and implementation complexities. The first major subsector is Digital
Health (which includes telemedicine, remote patient monitoring, mobile
health applications, electronic health records, and health information
systems), and telemedicine alone commands a leading 37.10 percent market share
in the Indonesian digital health landscape (KenResearch, 2025). The second
subsector, Medical Technology (commonly referred to as MedTech),
encompasses medical devices, diagnostic equipment, and increasingly
sophisticated wearable monitoring tools that generate continuous physiological
data streams.
The third
subsector, Biotechnology, encompasses biologics, pharmaceutical
innovations, genetic testing platforms, and precision medicine applications
that promise to transform disease management from population-based to
individually tailored interventions. Within the Indonesian context, health
technology startups have focused particularly on telemedicine to overcome the
formidable geographical barriers to care access; health monitoring solutions
for chronic disease management and preventive health promotion; integrated
health platforms that combine consultation, pharmacy, and laboratory services
within a single digital touchpoint; and BPJS Kesehatan integration strategies
designed to reach the more than 240 million Indonesians enrolled in the
national social health insurance program. Understanding these distinct
subsectors is essential for any entrepreneur or institutional leader seeking to
identify where their organizational competencies and available resources can
most productively intersect with genuine market needs.
The new digital
health paradigms have fundamentally shifted toward models that are more
patient-centric, preventive, predictive, and personalized, thereby creating
substantial value creation and research opportunities that are only beginning
to be systematically explored (JAIR, 2025). This shift implies that health
technology ventures most likely to achieve durable commercial success are not
those that merely digitize existing care delivery processes, but those that
fundamentally reimagine the patient journey in ways that generate measurable
clinical and economic value for all stakeholders in the ecosystem.
Key Players in
the Indonesian Health Tech Ecosystem
The Indonesian
health technology ecosystem has matured considerably since the early years of
digital health experimentation, with a distinct tier of established platform
leaders emerging alongside a robust pipeline of earlier-stage ventures. Halodoc has
emerged as the national leader, serving more than 20 million users and
achieving strategic integration with BPJS Kesehatan, a partnership that has
been instrumental in extending its reach to population segments that would
otherwise be inaccessible through premium-priced consumer channels. Other
significant platforms include Alodokter (which combines health information
services with telemedicine consultations), Good Doctor (providing
telemedicine and integrated health services), KlikDokter (delivering
telemedicine alongside extensive health content), and SehatQ (offering
health information and appointment booking capabilities).
Indonesian
health technology firms have collectively attracted approximately USD 230
million in venture funding over the past eight years, though the pace of
investment has moderated compared to the peak pandemic years as investors shift
their emphasis from user acquisition metrics toward demonstrating paths to
profitability (AsianInsiders, 2025). This maturation of investor sentiment is a
positive signal for the sector, indicating that health technology in Indonesia
is transitioning from an experimental phase characterized by subsidized growth
to a more sustainable commercial phase in which unit economics and clinical
outcomes carry greater weight in investment decisions.
An important
trend that health management professionals should monitor closely is the
growing international expansion ambitions of successful Indonesian health
technology companies, with Halodoc now operating in multiple Southeast Asian
markets. This expansion pattern reflects both the scalability of platform-based
digital health models and the degree to which Indonesia's population size and
digital penetration rates have enabled local companies to develop capabilities
and operational playbooks that are directly transferable to comparable markets
in the region. Institutions considering health technology partnerships or
investment decisions should factor this regional expansion dimension into their
strategic assessments.
Recent Trends
and Emerging Opportunities
Artificial
intelligence is rapidly emerging as the most consequential technological
frontier in Indonesian health technology, with potential contributions
estimated at USD 500 million or more to the national economy by 2030 through
improvements in diagnostic accuracy, clinical decision support, and health
system operational efficiency (AsianInsiders, 2025). Collaborative initiatives
between leading Indonesian universities, international research partners, and
the private sector are accelerating the development of AI-enabled health
applications that address uniquely Indonesian disease burden patterns, and
hospital managers who develop fluency in AI health applications today will be
substantially better positioned to leverage these tools as they reach clinical
readiness.
The rural
healthcare segment represents a particularly significant and underexplored
opportunity within the Indonesian health technology landscape, given that
geographic remoteness and limited specialist workforce density remain the
primary barriers to equitable health service access for large portions of the
national population. Government-supported initiatives, including collaborations
between national research institutions and regional universities, are actively
pursuing AI-enabled digital integration strategies to extend effective
healthcare reach into underserved areas, creating potential partnership
opportunities for health organizations willing to invest in inclusive service
delivery models (AsianInsiders, 2025). Additionally, the wearable health devices
market in Indonesia is expected to reach USD 1.5 billion by 2027, as Internet
of Things sensors paired with cloud-based AI analytics enable genuinely
proactive disease management paradigms that shift clinical value from reactive
treatment to predictive prevention.
B.
BUSINESS MODELS IN HEALTH TECHNOLOGY
Theoretical
Foundations of Business Model Design
A business model
constitutes the fundamental architecture through which a health technology
company creates, delivers, and captures value for its customers and investors.
Research on telehealth business models identifies four primary components that
together define the structural logic of any viable health technology venture:
the value proposition (the specific health problem addressed and the superior
solution offered), value co-creation (the roles played by all participating
stakeholders in generating the outcome), value communication and transfer (the
mechanisms through which the solution reaches end-users), and value capture
(the revenue model that sustains the enterprise financially) (Alami et al.,
2022). Entrepreneurs and institutional leaders who develop a rigorous
understanding of these four components are far better equipped to design
ventures that achieve durable product-market fit and attract the sustained
investment required for clinical-scale implementation.
Business models
in health technology must also be designed with a sensitivity to the particular
dynamics of healthcare markets that distinguish them from other commercial
sectors. Healthcare purchasing decisions frequently involve multiple
decision-makers with different objectives (clinicians prioritizing patient
outcomes, administrators prioritizing cost efficiency, and payers prioritizing
actuarial risk), and the entity that pays for a health technology solution is
frequently not the entity that uses it or the patient who ultimately benefits
from it. These principal-agent complexities mean that health technology
ventures must simultaneously construct value propositions that resonate with
multiple distinct stakeholders, and business model design must explicitly
account for how value is communicated and demonstrated to each of these
audiences throughout the commercial relationship.
B2B Models
(Healthcare Providers as Customers)
Business-to-business
(B2B) models in health technology position hospitals, clinics, and health
systems as the primary paying customer, with the technology company serving as
a specialized services or software vendor. The Subscription Licensing
Model is perhaps the most prevalent and commercially predictable B2B
approach, in which the vendor sells software or services to healthcare
institutions in exchange for recurring fees paid monthly, quarterly, or
annually. This model offers highly predictable recurring revenue streams and
encourages the development of long-term institutional relationships, but it
also entails high customer acquisition costs, lengthy enterprise sales cycles
that can extend from six to eighteen months in hospital settings, and the concentration
risk that comes from dependence on a relatively small number of large
institutional accounts.
The Licensing
with Revenue Sharing Model offers an alternative B2B structure in which
the vendor provides the enabling technology while the healthcare provider
contributes patient access and clinical infrastructure, with revenue shared
based on usage volume, transaction counts, or measurable clinical outcomes.
This alignment of incentives between vendor and provider can reduce the
friction of initial adoption by lowering the upfront financial commitment
required from the healthcare institution, but it introduces revenue variability
that can complicate financial planning and investor relations. The Managed
Services Model represents the highest-touch variant of B2B provision, in
which the vendor assumes responsibility not only for the software platform but
also for implementation, staff training, ongoing support, and system
maintenance, commanding premium pricing in exchange for the deeper operational
integration and reduced institutional burden that this comprehensive offering
provides.
B2C Models
(Direct-to-Consumer)
Business-to-consumer
(B2C) models reach individual patients and health-conscious consumers directly
through mobile applications, web platforms, and digital marketplaces, bypassing
institutional intermediaries and relying on consumer-grade acquisition
economics. The Direct-to-Consumer Model generates revenue through a
combination of subscription fees (monthly access to unlimited consultations or
premium features), pay-per-use charges (fees applied per consultation,
prescription refill, or laboratory test), in-app purchases of health education
content, wellness programs or nutraceutical products, marketplace commissions
from integrated pharmacy and laboratory partners, and advertising revenue from
pharmaceutical companies or health product vendors targeting the platform's
user base. The Indonesian market has proven to be receptive to D2C health
technology adoption, given the combination of high mobile penetration, a young
and digitally native demographic, and significant gaps in convenient access to
specialist care, particularly outside major urban centers.
However, D2C
models in health technology face formidable unit economics challenges that have
humbled many well-funded ventures globally. Consumer health applications
typically exhibit high churn rates as users cycle through episodic health
concerns and disengage once their immediate need is resolved, making customer
lifetime value (LTV) difficult to grow without persistent and costly
re-engagement strategies. Research on digital health business model
sustainability in lower-middle-income country contexts, which closely parallels
the Indonesian market environment, suggests that purely consumer-facing models
frequently struggle to achieve profitability at scale without institutional
anchor revenues or government program integration that can provide stable, recurring
transaction volumes (PMC, 2025). This evidence should inform the capital
allocation decisions of both entrepreneurs and hospital managers evaluating
whether to pursue or partner with D2C health technology ventures.
B2B2C Models
(Through Healthcare Providers or Institutional Partners)
Business-to-business-to-consumer
(B2B2C) models occupy a strategically advantageous intermediate position,
leveraging institutional relationships to access patient populations at scale
while retaining the consumer-facing value proposition that drives sustained
engagement and clinical impact. The Model Through Hospitals and Clinics sells
technology to healthcare providers, who then deploy it as part of their
patient-facing service portfolio, with revenue flowing either as a subscription
from the provider or on a pay-per-patient basis. This structure confers the
implicit endorsement of an established and trusted healthcare institution,
substantially reducing patient acquisition costs and accelerating adoption
among patient segments that might otherwise be skeptical of adopting health
technology from an unfamiliar vendor.
The Model
Through Insurance Companies leverages the insurer's existing membership
database and premium collection infrastructure to distribute health technology
services to large, pre-registered populations at minimal additional acquisition
cost. This model is particularly strategically relevant in Indonesia, where
BPJS Kesehatan's coverage of more than 240 million lives represents the largest
single pool of potential health technology users in the national market.
The Model Through Employers delivers wellness applications, mental
health support tools, and health screening programs to employees through
corporate procurement, with the employer paying for access and employees
receiving the service at no direct cost, an arrangement that aligns with
employer incentives to reduce absenteeism and improve workforce productivity.
In each of these B2B2C variants, the critical strategic challenge is
cultivating and sustaining the institutional partnership that serves as the
primary distribution channel, as the loss of a single major institutional
partner can devastate revenue overnight.
Hybrid Models
(Multiple Revenue Streams)
The most
commercially resilient health technology companies typically operate hybrid
models that deliberately diversify revenue across multiple streams, reducing
dependence on any single customer segment or commercial mechanism. A
telemedicine platform hybrid model might simultaneously generate revenue from
direct-to-consumer consultations, B2B licensing fees from hospital partners
deploying the platform under a co-branded arrangement, B2B2C revenue from
insurance company members accessing consultations as part of their benefit
package, marketplace commissions from integrated pharmacy and laboratory
services, and data analytics service fees from pharmaceutical companies or
public health institutions purchasing aggregated and anonymized population
health insights.
The research
literature on digital health business models consistently highlights that
hybrid revenue architectures not only reduce commercial risk but also create
multiple touchpoints with users and institutional partners that reinforce
platform stickiness and increase the barriers to competitive displacement
(Alami et al., 2022; JAIR, 2025). For hospital managers evaluating potential
health technology partnerships, the sophistication and diversification of a
vendor's revenue model should be considered an important indicator of
organizational resilience and long-term partnership viability. A vendor whose
commercial survival depends entirely on a single revenue stream, or on a single
institutional client, carries substantially higher partnership risk than one
whose revenues are distributed across a portfolio of mutually reinforcing
commercial relationships.
C.
VALUE PROPOSITION DEVELOPMENT
Problem-Solution
Fit
The foundational
prerequisite of any successful health technology venture is a precise and
validated understanding of the real healthcare problem that the company is
attempting to solve. An effective value proposition can be framed as: "Our
solution X addresses problem Y for population Z, who will be willing to pay
amount W because the unaddressed problem costs them approximately W-plus per
year in direct costs, foregone productivity, or diminished health
outcomes." Identifying problems worthy of this framework requires
systematic observation of healthcare workflows to locate inefficiencies, safety
hazards, and unmet patient needs; structured dialogue with both healthcare
providers and patients about their most persistent and burdensome pain points;
rigorous analysis of health data to understand disease prevalence, outcome
gaps, and cost drivers; and a disciplined evaluation of whether the identified
problem is sufficiently frequent (affecting large patient or provider
populations), sufficiently significant (carrying substantial impact on outcomes
or costs), and currently underserved by available solutions.
The process of
achieving problem-solution fit in health technology is iterative rather than
linear, and entrepreneurs who commit prematurely to a technology-first solution
without exhaustively validating the problem statement risk investing
substantial resources in solving a problem that users do not prioritize or are
unwilling to pay to address. Research on entrepreneurship and telemedicine
adoption among physicians in Indonesia demonstrates that performance expectancy
(the degree to which physicians believe that telemedicine will enhance their
clinical performance) and effort expectancy (the perceived ease of using
telemedicine technology) are the two most powerful predictors of adoption
intention, mediated by the physician's overall attitude toward digital health
tools (Safrizal et al., 2025). This finding carries a direct implication for
value proposition design: solutions that are engineered to demonstrably improve
clinical performance and minimize workflow disruption will encounter
substantially lower adoption resistance than those that impose significant
learning costs without proportionate clinical benefit.
Product-Market
Fit
Product-market
fit describes the stage at which a health technology product satisfies genuine
and strong market demand, as evidenced by growing user adoption, high
engagement and retention rates, positive organic word-of-mouth referrals,
customer willingness to pay at a price that generates viable unit economics,
and a clearly legible path to scalable expansion. Achieving product-market fit
in health technology is significantly more complex than in general consumer
applications because it requires simultaneously satisfying multiple independent
validation criteria: clinical efficacy (the product must demonstrably improve
health outcomes or process efficiency), regulatory compliance (the product must
meet applicable healthcare data protection and device certification
requirements), economic viability (the product must generate enough value to
justify the price charged and the adoption cost imposed), and usability (the
product must fit naturally into the existing workflows of the clinicians and
patients who will use it).
The Minimum
Viable Product (MVP) approach has become the standard methodology for
systematically pursuing product-market fit in health technology, enabling
ventures to launch with the minimum feature set necessary to solve the core
problem, gather real-world user feedback under operational conditions, and
iterate the product rapidly based on evidence rather than assumptions. The
digital health business model framework literature emphasizes that innovation
diffusion in the health technology sector is fundamentally contingent on the
active engagement and alignment of all stakeholders involved, ensuring that
digital tools effectively meet patient needs and improve health outcomes rather
than imposing technological change for its own sake (JAIR, 2025). Hospital
managers overseeing digital health implementations within their institutions
should apply an equivalent MVP discipline, piloting new technologies in limited
departmental contexts before committing to organization-wide deployment,
thereby preserving organizational learning capacity and minimizing disruption
to care delivery operations.
Competitive
Positioning
Effective
competitive positioning requires a health technology venture to articulate with
precision how its product differs from all available alternatives (including
the incumbent non-digital solution) and why its target customers should choose
it over those alternatives. Competitive differentiation in health technology
can be grounded in superior clinical outcomes (measurably better patient
results compared to competitive solutions), superior user experience (a more
intuitive and less disruptive interface that reduces training time and adoption
friction), superior economic efficiency (lower total cost of ownership
including implementation, training, maintenance, and support), superior
integration capability (seamless interoperability with existing electronic
health record systems and institutional workflows), superior clinical support
services (better-resourced customer success and clinical implementation teams),
or regulatory advantage (possessing existing regulatory approvals or
certifications that competitors have yet to obtain and that create a meaningful
time-to-market barrier).
Sustainable competitive advantage in health technology ultimately derives not from any single differentiating factor but from the accumulation of multiple reinforcing advantages that together create a durable moat against competitive displacement. Research on the sustainability of digital health business models in lower-middle-income country contexts highlights that ventures operating in markets with limited digital infrastructure and significant affordability constraints face particularly acute competitive pressures from lower-cost local alternatives, making it imperative for innovators to build competitive positions that combine technological differentiation with deep institutional relationships and local market knowledge that external competitors cannot easily replicate (PMC, 2025). For health administrators evaluating competitive digital health vendors, the depth and durability of a vendor's competitive moat should be assessed with equal rigor to the clinical and technical performance specifications of their product offering.
D.
CUSTOMER SEGMENTS
Healthcare
Providers
Healthcare
provider organizations constitute a diverse and internally differentiated
customer segment that requires carefully tailored engagement strategies at each
tier. Hospitals and large specialist clinics represent the most
commercially attractive accounts in terms of contract value, but they are also
the most demanding in terms of the procurement process, which typically
involves formal tender procedures, comprehensive security and compliance audits,
extended clinical and operational evaluation periods, and multiple
decision-making stakeholders including the Chief Information Officer, Chief
Executive Officer, Chief Medical Officer, and clinical department heads. The
extended sales cycle (commonly six to eighteen months for enterprise hospital
accounts) and the high cost of sales for this segment mean that health
technology vendors must carefully calibrate their addressable market
prioritization based on the strategic value and long-term revenue potential of
each institutional account.
Primary care
clinics (Puskesmas) and community health centers represent a
quantitatively much larger but individually lower-value segment with distinct
characteristics that require different product design and go-to-market
approaches. These organizations typically have limited information technology
staff, constrained procurement budgets, and minimal tolerance for complex
implementation projects, making ease of use and minimal onboarding burden
essential prerequisites for any solution targeting this segment. Private
practitioners occupy yet another distinct segment characterized by highly
individualized decision-making, a preference for solutions that deliver direct
and immediately visible patient benefits, and significant variation in digital
literacy and technology openness across the practitioner population.
Understanding these intra-segment differences is not merely an academic
exercise in market segmentation; it has direct practical implications for
product roadmap prioritization, sales channel design, pricing architecture, and
support model configuration.
Patients and
End-Users
The patient and
end-user segment is stratified along several behavioral and socioeconomic
dimensions that carry significant implications for product design, pricing
strategy, and distribution channel selection. Urban, young, and digitally
literate consumers represent the segment with the highest adoption
propensity for digital health applications; they are characteristically early
adopters, willing to experiment with new service models, and increasingly
concerned with data privacy and the clinical credibility of the platforms they
engage with. This segment has driven the initial growth of all major Indonesian
telemedicine platforms and continues to serve as the primary generator of product
feedback, user-generated reviews, and organic word-of-mouth referrals that are
disproportionately important for brand building in the early growth stages of a
health technology venture.
Middle-income
employed consumers represent the segment most likely to demonstrate
sustained willingness to pay for health technology services when the perceived
value (in terms of convenience, quality of care, and time savings relative to
seeking in-person services) is clearly articulated and consistently
delivered. Lower-income and rural populations are cost-sensitive by
necessity and typically access digital health services through subsidized
pathways such as BPJS Kesehatan integration, employer benefit programs, or
government-funded health promotion initiatives. Elderly and less digitally
literate populations present design and adoption challenges that are
frequently underestimated by technology-centric entrepreneurs; this segment may
require dedicated interface simplification, caregiver-assisted onboarding
workflows, and multilingual support in local languages to achieve meaningful
adoption levels. Health technology ventures that aspire to universal health
coverage alignment must invest in designing for the full spectrum of the user
population, not merely for the digitally native early adopters whose usage
patterns dominate initial market data.
Insurance
Companies and Government Payers
BPJS Kesehatan,
as the world's largest single-payer national health insurance program by
enrolled membership with coverage exceeding 240 million Indonesians, represents
both the most consequential institutional customer in the Indonesian health
technology market and the most complex to engage. Insurance companies and
government payers are primarily interested in health technologies that reduce
aggregate claims costs through efficiency gains, better chronic disease
management, or population health monitoring; improve measurable clinical
outcomes for high-cost conditions such as diabetes, cardiovascular disease, and
chronic respiratory illness; enhance member satisfaction and program retention;
and enable new service delivery models such as teleconsultation reimbursement
and remote monitoring that extend the program's effective coverage without
proportionately increasing infrastructure investment. The ability to
demonstrate return on investment in the language of actuarial risk reduction,
rather than clinical outcome improvement alone, is therefore a critical
capability for any health technology venture seeking to penetrate this segment.
Understanding the regulatory and procurement architecture governing BPJS Kesehatan and related government health programs is essential for health managers and entrepreneurs who wish to operate successfully within the formal health financing system. Government contracts can provide substantial and stable transaction volumes, but they involve complex multi-stage procurement processes, significant price negotiation pressure, and political risk factors that differ fundamentally from the commercial risk profile of private sector health technology sales. Entrepreneurs who develop early and sustained working relationships with government health program administrators are substantially better positioned to navigate this environment than those who attempt to enter government procurement channels without prior institutional familiarity and trust-building investment.
E.
REVENUE MODELS: DETAILED ANALYSIS
Table
9.1. Revenue Models; It’s Advantages and Challenges
|
Revenue Model |
How It Works |
Best For |
Advantages |
Challenges |
|
Subscription
(SaaS) |
User
pays recurring fee for platform access |
B2B
(providers, insurers) and some B2C premium tiers |
Predictable
recurring revenue, long-term institutional relationships |
High
customer acquisition cost, churn risk in B2C |
|
Pay-per-Use |
Charge
per completed transaction |
Telemedicine
consultations, laboratory services, pharmacy refills |
Revenue
aligned directly with value delivered |
Variable
and unpredictable revenue, consumer resistance at point of use |
|
Freemium |
Free
basic tier, premium features charged |
B2C
health applications, consumer health information platforms |
Rapid
large-scale user base acquisition, viral referral potential |
Conversion
rate challenges, free-tier users generate cost without revenue |
|
Marketplace
Commission |
Platform
takes a percentage of partner transactions |
Integrated
platforms offering pharmacy, laboratory, and home visit services |
Revenue
scales with ecosystem growth without proportionate cost increase |
Dependency
on partner relationships, margin compression under competitive pressure |
|
Advertising |
Revenue
from health product vendors advertising to user base |
B2C
applications with large, engaged audiences |
Scalable
with minimal direct customer acquisition burden |
User
experience degradation, potential brand credibility risk |
|
Outcomes-Based |
Revenue
contingent on achievement of defined health outcomes |
B2B2C
through insurers, enterprise employer wellness programs |
Fully
aligned incentives, justifies premium pricing with demonstrated value |
Complex
outcome measurement, delayed payment cycles |
|
Licensing
(White-Label) |
Technology
licensed to other companies for rebranding and resale |
B2B
technology infrastructure providers |
Scalable
model with reduced customer acquisition burden |
Lower
net margin, limited direct control over end-user experience |
Indonesian-Specific
Revenue Considerations
The Indonesian
health technology revenue environment presents a distinctive set of structural
considerations that fundamentally shape the viability of different revenue
model choices. BPJS Kesehatan integration creates substantial opportunities for
volume-based revenue models but simultaneously introduces regulatory complexity
related to service reimbursement classifications, clinical pathway compliance
requirements, and the administrative overhead of interfacing with government
payment systems. The growing adoption of digital payment infrastructure,
including GoPay, OVO, Dana, and ShopeePay, has meaningfully expanded the
addressable market for health technology payment collection, particularly in
geographic areas where bank account penetration remains below fifty percent of
the adult population.
Consumer price
sensitivity in the Indonesian market frequently necessitates freemium
architectures or aggressively tiered pricing structures for consumer-facing
health applications, as the premium consumer health services market remains
relatively small in absolute terms despite Indonesia's large aggregate
population. Health technology entrepreneurs who attempt to transplant pricing
models developed in high-income country markets without adjustment for
Indonesian purchasing power parity will consistently encounter adoption
barriers that their clinical and technological superiority cannot overcome.
Government and institutional procurement contracts can provide revenue
stability and volume, but they involve price negotiation dynamics that
typically require significant margin concessions relative to direct commercial
sales, and ventures must model these margin implications carefully before
treating government procurement as a primary revenue strategy.
F.
GO-TO-MARKET STRATEGY
Product
Development: The MVP Approach
The Minimum
Viable Product methodology represents the most evidence-validated approach to
health technology product development, enabling ventures to reach the market rapidly
with a tightly scoped feature set, gather real operational feedback under live
user conditions, and iterate the product based on empirical evidence before
committing to the substantial engineering investment required for a
full-feature platform. For a telemedicine startup, an appropriately scoped MVP
would include the core capabilities of video consultation, patient appointment
scheduling, prescription documentation, and payment processing, deliberately
deferring more complex capabilities such as advanced population analytics,
AI-assisted diagnostic support, and multi-EHR integration to subsequent
development cycles informed by user adoption data.
The MVP
discipline protects entrepreneurial ventures from one of the most common and
costly failure modes in health technology, namely the tendency to over-engineer
initial products in pursuit of comprehensiveness, thereby consuming substantial
capital and time before receiving any real-world validation of core
assumptions. The research literature on digital health business models
consistently identifies customer-centricity and iterative development
responsiveness as the defining characteristics of successful digital health
startups, and organizations that build systematic feedback loops between user
behavior data, clinical outcome measurement, and product development
prioritization are substantially more likely to achieve durable product-market
fit than those that rely primarily on initial design specifications (JAIR,
2025). Hospital managers overseeing institutional technology procurement should
apply equivalent principles of incremental adoption, beginning with limited
departmental pilots before committing to organization-wide deployment.
Launch Strategy
A structured
three-stage launch approach mitigates the operational and reputational risks
inherent in introducing health technology solutions to populations whose
wellbeing depends on reliable service delivery. The Pilot Program stage
restricts the initial deployment to a carefully selected geographic area or
customer segment, typically chosen for its combination of favorable adoption
characteristics and organizational readiness to support the operational demands
of early-stage technology integration. The pilot generates the clinical
evidence, operational case studies, and user testimonials required to build a
compelling sales narrative for broader market expansion.
The Soft
Launch stage makes the product available to a broader audience with
limited formal marketing investment, allowing the venture to build its user
base organically through early adopter channels while continuing to refine
operational processes and product features in response to real-world usage
data. The Public Launch stage constitutes the formal market entry
announcement, supported by a coordinated press and communications campaign,
stakeholder outreach, and marketing investment calibrated to the venture's
funding stage and target customer acquisition cost targets. This staged
approach to market entry is particularly important in healthcare contexts,
where any publicized operational failure or patient safety incident during the
early adoption phase can impose reputational damage that is disproportionately
difficult to recover from in an industry where trust is the foundational
currency of all commercial relationships.
Marketing and
Customer Acquisition
Marketing and
customer acquisition strategies in health technology must be precisely
calibrated to the commercial structure of each customer segment, as the
channels, messages, and decision-making timelines differ dramatically between
institutional B2B buyers and individual consumer users. For B2B sales, the
most productive investment is typically in demonstrating clinical and
operational value through peer-reviewed case studies, structured pilot programs
with transparent outcome reporting, direct enterprise sales engagement,
industry conference participation with clinical evidence presentation, and
thought leadership content that positions the company as a trusted partner in
institutional digital transformation rather than merely a technology
vendor. For B2C acquisition, the primary channels are mobile app store
optimization for search visibility, targeted digital advertising across search
and social media platforms, earned media through partnerships with health
journalists and influencers, and the organic word-of-mouth referrals that
represent the most cost-efficient and credible form of consumer recommendation.
For B2B2C models,
the critical investment is in partnership development with healthcare
providers, insurance companies, and employers, as the institutional partner
serves simultaneously as the primary distribution channel, the source of
commercial legitimacy, and the mechanism for reaching patient populations at
scale. The cost of partnership development in B2B2C models is frequently
underestimated by entrepreneurs with a technology background, as it involves
sustained relationship investment with senior institutional leaders who operate
within complex organizational cultures and decision-making structures that
require patience, persistence, and a demonstrated commitment to the partner's
institutional interests alongside the vendor's commercial objectives. Research
on digital health adoption emphasizes that institutional trust and relational
legitimacy are prerequisites for commercial success in the healthcare sector,
and these cannot be manufactured through advertising investment alone (Safrizal
et al., 2025).
G. SCALING
CHALLENGES
Regulatory
Compliance
Health
technology companies operating at scale must navigate a layered and frequently
evolving regulatory environment that spans healthcare service regulations,
financial transaction compliance, data protection law, and increasingly,
specific AI governance guidelines. In the Indonesian context, the Personal Data
Protection Law enacted in 2022 establishes rigorous requirements for the
collection, storage, processing, and cross-border transfer of personal data,
including health data, and non-compliance carries substantial civil and
reputational penalties that can permanently damage institutional trust.
Healthcare service delivery regulations impose additional licensing
requirements, clinical safety standards, and professional accountability
obligations that vary by service type and delivery modality, and ventures that
fail to invest in robust regulatory affairs capability from the earliest stages
of development routinely discover that compliance remediation is substantially
more costly and disruptive than proactive compliance design.
The strategic
implication for health technology entrepreneurs is unequivocal: regulatory
compliance must be architected into the product, operations, and governance
structure from the outset, not retrofitted after scaling pressures have already
embedded non-compliant practices throughout the organization. Research on the
sustainability of digital health business models in lower-middle-income country
contexts, which closely parallels the Indonesian regulatory environment,
identifies regulatory navigation capability as one of the primary determinants
of long-term market survival for health technology ventures, as regulatory
frameworks in these markets are typically in active development and subject to
significant revision that can fundamentally alter the commercial viability of
specific business model architectures (PMC, 2025). Hospital managers who serve
as institutional partners or anchor customers for health technology vendors
carry a shared compliance responsibility and should conduct rigorous vendor due
diligence on regulatory compliance status before entering commercial or
clinical deployment agreements.
Quality
Assurance
Healthcare is an
inherently high-stakes operating environment in which software errors, data
integrity failures, or clinical decision support inaccuracies can directly
compromise patient safety, making quality assurance an operational imperative
rather than a discretionary engineering investment. A comprehensive quality
assurance program for health technology must encompass unit and integration
testing of all software components, clinical validation of any functionality
that makes clinical claims or informs clinical decisions, security testing and
penetration testing to identify and remediate vulnerabilities before they can
be exploited in production environments, performance testing to ensure system
reliability and responsiveness under peak load conditions, and structured user
acceptance testing with actual clinical users in representative operational
contexts.
The quality
assurance challenge scales significantly in complexity as a health technology
platform grows in user volume and data processing complexity, and ventures that
fail to invest in automated testing infrastructure, continuous integration and
deployment pipelines, and dedicated clinical safety review processes will find
their quality assurance capacity increasingly insufficient relative to the rate
of product development. Digital health business model research consistently
identifies quality and reliability as critical determinants of institutional
adoption, as healthcare provider organizations have exceptionally low tolerance
for technology systems that create operational disruption or introduce clinical
risk, and a single high-profile system failure can reverse months of carefully
cultivated institutional trust (Alami et al., 2022). The operational maturity
of a health technology vendor's quality assurance processes should therefore be
a primary criterion in the due diligence conducted by hospital managers when
evaluating potential technology partnerships.
Team Building
and Organizational Development
Scaling a health
technology venture from an entrepreneurial startup to a mature operational
organization requires building a leadership team with genuinely diverse
expertise that spans the full spectrum of capabilities required for sustainable
growth. Technical product and engineering leadership provides the foundation
for platform scalability and security architecture. Clinical expertise ensures
that product design decisions maintain alignment with genuine clinical needs,
professional practice standards, and patient safety requirements. Regulatory
and compliance leadership navigates the complex requirements of healthcare
operating licenses, data protection law, and government program integration.
Business development and commercial leadership generates the revenue growth
required to sustain operational investment. Financial and operational
leadership manages the scaling processes, cost structures, and capital
allocation decisions that determine whether growth translates into sustainable
commercial success.
Health
technology entrepreneurs who come from clinical or technical backgrounds
frequently underestimate the organizational complexity of scaling and the
degree to which business leadership capability is as determinative of venture
success as clinical or technological innovation. Research on digital health
startup success patterns consistently identifies the composition and
complementarity of the founding team as one of the three most powerful
predictors of venture outcome, alongside the quality of problem-solution fit
and the adequacy of available capital (JAIR, 2025). For hospital managers who
lead institutional digital health transformation initiatives, the lesson is
equally applicable: successful implementation requires assembling a
cross-functional project team that brings together clinical, technological,
operational, and change management expertise in a structure that gives each
discipline genuine authority and accountability.
Infrastructure
Scaling
As a health
technology platform grows in user volume, data processing complexity, and
geographic distribution, the underlying technical infrastructure must scale in
a manner that maintains service reliability, data security, and system
performance within acceptable boundaries. Cloud infrastructure architecture is
the near-universal solution for health technology platforms at scale, offering
the dynamic capacity expansion required to accommodate usage spikes (for
instance, during epidemic events or government health awareness campaigns)
without the capital-intensive investment in dedicated hardware that
characterized an earlier generation of healthcare information systems. Database
architecture must be designed from the outset with scale in mind, as retrospective
database re-architecture under production load conditions is one of the most
costly and operationally disruptive technical challenges that health technology
companies encounter during their growth phase.
Security
measures must scale in parallel with platform growth, as the aggregate value of
the health data held within a growing platform increases proportionately with
user volume, making the platform an increasingly attractive target for
cybersecurity adversaries. Integration infrastructure for connecting with the
growing number of institutional customer systems (each with its own EHR
platform, laboratory information system, and billing architecture) represents a
particularly significant engineering investment that is frequently
underestimated in early-stage product roadmaps. Health administrators managing
institutional technology portfolios should require explicit documentation from
health technology vendors regarding their infrastructure scalability architecture,
data residency policies, disaster recovery capabilities, and cybersecurity
certifications before entering into agreements that involve the storage or
processing of protected health information.
H.
SUCCESS CASES
Halodoc:
Indonesia's Telemedicine Pioneer
Halodoc stands
as the most instructive and thoroughly documented success story in the
Indonesian health technology ecosystem, having achieved more than 20 million
registered users and a market position of genuine national significance.
Several intersecting factors explain the company's trajectory. Its pre-pandemic
launch timing positioned it to capitalize on the extraordinary behavioral
change acceleration induced by COVID-19, allowing it to convert crisis-driven
first-time users into established patients with durable telemedicine usage
habits. Its decision to evolve beyond a single-service telemedicine offering
into a comprehensive integrated health platform (combining medical
consultations, pharmacy services, laboratory testing, and home visit capabilities
within a single user experience) created a level of platform stickiness and
cross-service revenue diversification that single-service competitors could not
replicate.
The strategic
partnership with BPJS Kesehatan represents perhaps the most consequential
single commercial decision in Halodoc's development, as it transformed the
platform from a premium consumer service accessible primarily to urban,
middle-class users into a universally accessible healthcare tool available to
any of the more than 240 million BPJS Kesehatan members nationwide. This
partnership exemplifies a principle that has broad applicability for health
technology ventures operating in universal health coverage environments: the
ability to integrate with the dominant public health financing system is not
merely a commercial advantage but a strategic prerequisite for achieving the
population-level health impact that distinguishes transformative health technology
platforms from those with narrow demographic reach. The management capability
to navigate the complex operational and regulatory demands of this integration
was as critical to the outcome as the platform's underlying technology.
Global Reference
Cases
Teladoc Health in
the United States represents the archetypal case study of a telemedicine venture
achieving sustainable large-scale commercial maturity through a disciplined
strategy of partnership with major insurance companies and large employers,
outcomes-based contracting that aligned the company's revenue incentives with
demonstrable improvements in chronic disease management, and systematic
platform expansion into adjacent clinical domains that increased the
addressable market while leveraging existing institutional relationships.
Teladoc's journey from a startup focused on routine telehealth consultations to
a publicly traded enterprise serving tens of millions of users across multiple
clinical specialties and care modalities illustrates the compound commercial
advantages that accrue to health technology platforms that achieve genuine clinical
credibility and the institutional trust that follows from demonstrated outcomes
performance.
Ro (formerly
Roman Health) in the United States offers a contrasting but equally instructive
case study in the power of focused niche positioning as an initial go-to-market
strategy. By concentrating initially on a small number of underserved men's health
conditions (erectile dysfunction, hair loss, smoking cessation) where the
patient population had high willingness to pay for discreet, convenient, and
stigma-free access to clinical care, Ro achieved rapid product-market fit and
sustainable unit economics in its core markets before expanding into additional
chronic condition categories. This case illustrates a principle that is
directly applicable to the Indonesian context: health technology ventures that
attempt to address every healthcare need simultaneously (the platform-first
approach) frequently underperform relative to those that achieve deep
problem-solution fit in a specific clinical domain first and then expand
incrementally from a position of demonstrated clinical and commercial strength.
Summary
Health
technology entrepreneurship offers extraordinary opportunities for creating
solutions that address genuine and consequential healthcare problems at
population scale. The Indonesian digital health market, with its combination of
large underserved population, accelerating digital infrastructure development,
strong government commitment to health digitalization, and a maturing ecosystem
of institutional investors and platform leaders, presents a particularly
favorable environment for both entrepreneurial ventures and institutional
organizations seeking to develop digital health capabilities. Success in this
environment requires a rigorous analytical understanding of the market
landscape, a disciplined approach to business model design and value proposition
development, a sophisticated appreciation of the diverse customer segments and
their distinct decision-making architectures, an operationally sound
go-to-market strategy, and a realistic assessment of the scaling challenges
that must be proactively managed for sustainable organizational growth. The
digital health business models and entrepreneurial strategies examined in this
module are directly applicable to hospital managers and health administrators
who bear institutional responsibility for digital transformation, as the
analytical frameworks and strategic principles that guide successful health
technology venture development are the same principles that guide successful
institutional health technology adoption.
References
Alami, H.,
Lehoux, P., Denis, J. L., Motulsky, A., Petitgand, C., Savoldelli, M., &
Rouquet, R. (2022). Telehealth business models and their components: Scoping
review. JMIR Medical Informatics, 10(4), e32914. https://pmc.ncbi.nlm.nih.gov/articles/PMC9006135/
AsianInsiders.
(2025, November 18). Indonesian digital health industry enters its next
phase. AsianInsiders. https://asianinsiders.com/2025/11/18/growth-of-indonesian-digital-health-industry/
KenResearch.
(2025). Indonesia digital health market outlook to 2030.
KenResearch. https://www.kenresearch.com/industry-reports/indonesia-digital-health-market
KenResearch.
(2025). Indonesia telemedicine and digital health market.
KenResearch. https://www.kenresearch.com/indonesia-telemedicine-and-digital-health-market
MarketResearchIndonesia.
(2025). Indonesia telemedicine market and the future of care.
MarketResearchIndonesia. https://marketresearchindonesia.com/insights/articles/indonesia-telemedicine-market-future-of-care
PMC. (2025).
Sustainable by design: Digital health business models in low-income and
lower-middle-income countries. JAMIA Open, Article 12547002. https://pmc.ncbi.nlm.nih.gov/articles/PMC12547002/
Safrizal, H. A.,
Sukmayanti, A., & Hidayat, R. (2025). Entrepreneurship and innovation in
telemedicine adoption among physicians in Indonesia. Applied Technology
and Technopreneurship, 4(2). https://att.aptisi.or.id/index.php/att/article/view/707
Statista.
(2024). Digital health market — Indonesia: Revenue in the digital
health market projected to reach US$2.64 billion in 2025. Statista Market
Forecast. https://www.statista.com/outlook/hmo/digital-health/indonesia
Tarasenkova, A.,
Thommandru, A., Guzman, E., & Anand, N. (2025). The business model
framework for digital health start-ups in Europe. Journal of Artificial
Intelligence Research, 4(1). https://jas.bayern/index.php/jair/article/view/19
Comments
Post a Comment